Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials ; volume:6 ; number:1 ; day:4 ; month:1 ; year:2013 ; pages:1-12 ; date:12.2013
Journal of hematology & oncology ; 6, Heft 1 (4.1.2013), 1-12, 12.2013
- Urheber
-
Kharfan-Dabaja, Mohamed A.
Hamadani, Mehdi
Reljic, Tea
Nishihori, Taiga
Bensinger, William
Djulbegovic, Benjamin
Kumar, Ambuj
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-6-2
- URN
-
urn:nbn:de:101:1-2021082106110934609692
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kharfan-Dabaja, Mohamed A.
- Hamadani, Mehdi
- Reljic, Tea
- Nishihori, Taiga
- Bensinger, William
- Djulbegovic, Benjamin
- Kumar, Ambuj
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study
Autologous haemotherapy
Current status of autologous stem cell transplantation for multiple myeloma
Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study
Autologous haemotherapy
Current status of autologous stem cell transplantation for multiple myeloma
Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study
Autologous haemotherapy